Progenity
Eric d’Esparbes brings more than 25 years of financial and executive experience in strategic planning and fund-raising functions for both private and public companies.
Most recently, he was the CFO and interim Principal Executive Officer of Innoviva, Inc. (NASDAQ:INVA), a publicly traded biotechnology company managing a portfolio of asthma and chronic obstructive pulmonary disease medicines, which are sold globally by GlaxoSmithKline. During his time at Innoviva, Mr. d’Esparbes led the optimization of the company’s capital structure and helped develop and implement a strategic plan to transition the company to a higher margin business. Prior to this, he held leadership positions as CFO for Joule Unlimited, Vice President of Finance for global energy company, AEI, Inc., and CFO for Meiya Power Company (now CNG New Energy), where he collaborated with large private equity investors to raise and optimize capital. In his previous roles, he was responsible for profit and loss management of up to $3.5 billion annual global sales. Mr. d’Esparbes holds a bachelor’s degree from Hautes Études Commercial in Montréal, Canada.
This person is not in any offices
Progenity
Progenity helps patients and their families Prepare for Life, with medically relevant health information starting before conception, through pregnancy and adulthood. Using our highly-complex molecular diagnostic testing, healthcare providers can access the most advanced genomic technology to guide patient care at critical life stages.